Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for pharmaceutical industry
[Book Review] The Protection of Traditional Knowledge at the Frontiers of Drug Discovery [Book Review] The Protection of Traditional Knowledge at the Frontiers of Drug Discovery Reviewed by Jocelyn Bosse on Friday, June 20, 2025 Rating: 5
"Competition Law in the Pharmaceutical Sector" returns to Brussels with IPKat readers’ discount "Competition Law in the Pharmaceutical Sector" returns to Brussels with IPKat readers’ discount Reviewed by Eleonora Rosati on Thursday, October 26, 2023 Rating: 5
Beyond exclusion of pharmaceutical products from patentable subject matter as a solution to limited access to medicines in Africa Beyond exclusion of pharmaceutical products from patentable subject matter as a solution to limited access to medicines in Africa Reviewed by Chijioke Okorie on Wednesday, July 31, 2019 Rating: 5
SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) Reviewed by Dr Rose Hughes on Friday, June 28, 2019 Rating: 5
BREAKING: CJEU delivers another blow to SPC owners in Abraxis Article 3(d) (or 1(b)) battle BREAKING: CJEU delivers another blow to SPC owners in Abraxis Article 3(d) (or 1(b)) battle Reviewed by Annsley Merelle Ward on Thursday, March 21, 2019 Rating: 5
Does Allergan's Saint Regis Mohawk Tribe transactional move "rip off consumers"? Does Allergan's Saint Regis Mohawk Tribe transactional move "rip off consumers"? Reviewed by Annsley Merelle Ward on Monday, September 18, 2017 Rating: 5
The Evolution of U.S. Law and the Bio-Pharmaceutical Industry The Evolution of U.S. Law and the Bio-Pharmaceutical Industry Reviewed by Mike Mireles on Wednesday, April 06, 2016 Rating: 5
AIPPI Congress Report 3: Biosimilars - into the great unknown? AIPPI Congress Report 3: Biosimilars - into the great unknown? Reviewed by Annsley Merelle Ward on Wednesday, September 17, 2014 Rating: 5
Generics behaving badly? BMS v Teva illustrates UK judicial mood towards generic launch plans (Part II) Generics behaving badly? BMS v Teva illustrates UK judicial mood towards generic launch plans (Part II) Reviewed by Annsley Merelle Ward on Sunday, July 28, 2013 Rating: 5
Generics behaving badly? BMS v Teva illustrates UK judicial mood towards generic launch plans (Part I) Generics behaving badly? BMS v Teva illustrates UK judicial mood towards generic launch plans (Part I) Reviewed by Annsley Merelle Ward on Sunday, July 28, 2013 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.